Isofagomine tartrate

Drug Profile

Isofagomine tartrate

Alternative Names: afegostat tartrate; AT 2101; HGT-3410; isofagomine-ERT combo therapy; Plicera; Plicera-ERT combo therapy

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk; University of Maryland, Baltimore
  • Developer Amicus Therapeutics
  • Class Antihyperglycaemics; Imino pyranoses; Pharmacological chaperones; Piperidines; Small molecules
  • Mechanism of Action Glucosylceramidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I

Highest Development Phases

  • No development reported Gaucher's disease type I
  • Discontinued Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gaucher's disease type I(Combination therapy) in USA (PO, Capsule)
  • 15 Dec 2016 Biomarkers information updated
  • 28 Feb 2012 Isofagomine tartrate is still in preclinical trials for Gaucher's disease (combination therapy) in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top